Background: We have recently suggested that bolus 5-fluorouracil (5-FU) may work via a RNA directed mechanism while continuous infusion 5-FU may kill cells via a thymidylate synthase related pathway. It may thus be possible to selectively modulate each schedule biochemically. We have compared an alternating regimen of bolus and continuous infusion 5-FU, selectively modulated for the schedule of administration, with modulated bolus 5-FU in advanced colorectal cancer patients.
Introduction
The treatment of colorectal cancer patients has met substantial improvements in the last several years. This is true for both the adjuvant and the advanced setting. The demonstration that: a) six months of adjuvant chemotherapy reduces the odds of relapsing by 30% in stage III patients [1] , b) chemotherapy doubles the median survival time of patients with advanced disease, compared to untreated controls [2, 3] , c) chemotherapy significantly prolongs their symptom-free survival [4] , and d) second-line chemotherapy prolongs the survival of patients compared to best supportive care [5, 6] are recent major achievements in this neoplasm.
These results are mainly based upon a more rational use of 5-fluorouracil (5-FU) nevertheless the growing enthusiasm in this field is primarily connected to the use of new classes of agents that promise to be very active in this disease: the camptothecin analogue irinotecan [7] and the new platinum analogue oxaliplatin [8] . Both these agents, initially studied as second line chemotherapy, are now under investigation as first-line treatment of advanced colorectal cancer in a variety of combinations with 5-FU. And the same combinations are about to be tested in the adjuvant setting as well.
Unfortunately, these new agents are burdened with substantial toxicity and it is still to be proven that these combinations are superior to the best schedule of modulated 5-FU.
Our recent work has been focused on the hypothesis that 5-FU may be two different drugs depending on its schedule of administration [9] , bolus and CI. We have in fact demostrated that repeated short term exposures of human colon cancer cells to 5-FU in vitro produced resistance via an RNA-related mechanism, while resistance to continuous exposure 5-FU was mediated by a DNA-directed mechanism [10] . In addition continuous exposure to 5-FU was cytotoxic to cells resistant to bolus 5-FU in the same in vitro model [11] . We have thus suggested that it may be possible to selectively modulate each schedule biochemically: enhancement of 5-FU cytotoxicity may be maximal when the fluoropyrimidine is given as a CI, while channelling 5-FU into RNA using MTX or trimetrexate may improve results of bolus 5-FU [9] .
An alternating regimen of selectively modulated bolus and CI 5-FU, was then developed and tested in two phase II studies [12, 13] obtaining response rates in the range of 40%, progression-free survival (PFS) of 8-10 months and median survival times of 16-19 months at the cost of low toxicity. The following report regards the randomized comparison between our new schedulespecific regimen and modulated bolus 5-FU as first-line treatment of advanced colorectal cancer patients in an effort to define the best 5-FU schedule that could be combined with the new agents showing promising activity against this disease. Figure 1 Design of the study. One cycle is eight weeks in each arm. The experimental drug regimen (E) consisted of two parts. In the first part of the cycle, patients were given MTX 200 mg/m 2 i.v. diluted in 500 ml D 5 W, infused in one hour, day 1; 5-FU 600 mg/m 2 i.v. bolus, day 2; LV rescue consisted of 20 mg/m 2 p.o. every six hours x 6, days 2-3, starting after 5-FU bolus. Sequential MTX -> 5-FU was repeated after two weeks. In the second part of the cycle, patients were given 5-FU, 200 mg/m 2 /day CI x 3 weeks, and LV, 20 mg/m 2 i.v. bolus every week. In the control arm (C) patients were given only sequential MTX -» 5-FU as in the first part of E. c) the experimental nature of this treatment protocol. Upon study entry all patients were given an outline of drug treatment along with written information about the anticipated toxicities.
Patients and methods

Kb
MTX-*-PU MTX-»-FU
Patient selection and randomization procedures
Patients from 19 Italian centers were entered in this study if they satisfied all of the following requirements. 1) Biopsy-proven relapsed or metastatic adenocarcinoma of the colon or rectum. There were three exceptions to the requirement for histologic confirmation of metastatic disease in patients with a history of resection for colorectal cancer no longer than five years before, a) Patients with two or more pulmonary nodules enlarging on serial chest X-rays and no other disease site accessible to biopsy, b) Patients with two or more hepatic nodules and CEA > 10 ng/ml in at least two consecutive determinations, c) Patients with pelvic mass and new onset presacral pain. 2) The disease had to be bi-dimensionally measurable. Appropriate radiologic examinations had to be obtained no longer than one month before the beginning of treatment to serve as a baseline for serial evaluation of the patient's disease status. 3) No prior chemotherapy for metastatic disease was allowed. Adjuvant chemotherapy was not an exclusion criterion provided that treatment was completed longer than one year before study entry. Radiation therapy was allowed as long as it did not encompass the indicator lesions. 4) ECOG performance status had to be <3, serum bilirubin and creatinine levels less than 3.0 mg/100 ml and 1.8 mg/100 ml, respectively; and GOT and GPT less than four times the institutional upper limits of normal. Granulocyte counts of greater than 1500/mm 3 and platelet counts of greater than 100,000/mm 3 were required. Additional eligibility criteria included geographic accessibility, the absence of clinically relevant ascites and the absence of other medical conditions clearly contraindicating the administration of any chemotherapy Patients were randomly assigned to the experimental treatment or to the control treatment by phoning a central coordinating office. A randomization list was generated for each participating center. Randomization lists were balanced within blocks of different size.
This protocol was approved by the Ethical Committee of the Istituto Nazionale per la Ricerca sul Cancro in Genoa. Informed consent was required. On the first and second visit before treatment administration patients were informed about: a) the presence of metastatic colorectal cancer, b) the poor prognosis of their disease and
Treatment plan
The experimental arm, E, consisted of the alternating regimen of bolus and infusional 5-FU that we previously tested in a phase II trial and that was derived from two well studied regimens: sequential MTX and bolus 5-FU [14] and CI 5-FU modulated by LV [15] . Figure 1 . After one week of rest, the second cycle was started on day 57. The entire duration of the cycle is thus eight weeks. CI 5-FU was administered through implanted catheters and a venous Port-a-cath (Pharmacia) connected to a portable programmable external pump (CADD-1, Pharmacia) or disposable elastomeres (Baxter). The infusional cassettes or elastomeres were changed weekly if no toxicity developed earlier.
The control arm consisted of sequential MTX -> 5-FU with a 24-hour interval between the agents, and LV rescue (20 mg/m 2 ) as reported by Marsh [14] . This regimen was identical to the 'bolus part' of the experimental arm of the study, except for the fact that it was continued until progression without alternating with CI 5-FU. The reasons for choosing this regimen as comparator arm in this randomized study are explained in the discussion section.
Toxicily was evaluated every two weeks for the bolus part and every week for the infusional part of the treatment. Complete blood counts were obtained at these intervals. Liver function tests, blood urea nitrogen creatinine and electrolytes were obtained monthly.
Dose modification criteria for the MTX -» 5-FU regimen were as follows: no dose-reduction for gastrointestinal grade 1 and 2 toxicity. For grade 3 diarrhea or mucositis, the treatment was delayed until recovery and the doses of MTX and 5-FU of the next cycle were decreased by 50%. The dose was reduced by 50% also for a WBC of < 3000/mm 3 or platelets < 75,000/mm 3 on the day of re-cycle. Treatment was discontinued in case of grade 4 non-hematologic toxicity.
CI 5-FU was discontinued upon the first symptoms and signs of mucositis and/or palmar-plantar dysaesthesia/burning, and resumed when these symptoms abated. However, that was not always possible because, despite full explanation and extensive written information about the risk of continuing treatment, several patients tended to disregard the 'first symptoms and signs', presenting to medical attention only when severe mucositis (grade 3) was in progress. In those cases, the infusion was resumed at a reduced 5-FU dose (50%). No dose modification was planned for LV.
The duration of treatment depended on outcome. Upon documentation of complete response (CR), two additional months of treatment were given. In the case of partial response (PR), or stable disease (SD), the treatment was continued until two consecutive CT scans, obtained two months apart, failed to demonstrate further tumor shrinkage. At that point, chemotherapy was stopped and the disease was monitored every two months; in these patients the same regimen was resumed two to six months later upon documentation of tumor progression. No guidelines were given as regarded second-line chemotherapy.
Response evaluation
Patients who received at least two months of therapy with adequate pretreatment and follow-up radiographic studies were considered assessable for response. Measurable tumor was defined as a known tumor mass that could be clearly measured in two dimensions by imaging techniques. A CR was defined as complete disappearance of all evidence of tumor and return of abnormal tests to normal levels for a minimum of eight weeks. A PR was defined as a 50% or greater reduction in the sum of the products of the largest perpendicular diameters of all measured lesions, in the absence of progression of any lesion or the appearance of any new lesion. SD was defined as too small a change in measurable disease to meet the requirements for PR or progression, without the appearance of new lesions for a period of at least eight weeks, provided that there was no worsening of symptoms. Disease progression was defined as the development of new areas of malignant disease, or an increase by at least 25% in measurable disease compared to the baseline value, or a 25% increase in the size of lesions over that attained at best response.
Indicator lesions were measured at each successive cycle. The baseline tumor areas and their variations at each successive evaluation were expressed in cm 2 . Toxicity is expressed according to the WHO criteria.
PFS and and overall survival were measured from the date of randomization to the date of disease progression as defined above, or to the date of death, respectively. Quality of life was measured on patients from 4 recruiting centers using the Rotterdam Symptom Checklist method that include 8 questions of psychological domain, 22 symptom-related and 8 activity related questions [16] . Forms were given every two weeks to patients in C and on days 1, 14, 29, and 49 to patients in E.
Statistical methods
The statistical design was based upon an anticipated 20% difference in response rate. This figure was derived from our previous studies suggesting a IO%-2O% response rate to modulated bolus 5-FU [17, 18] and a 40% response rate to the schedule-specific biochemical modulation regimen [12, 13] . To detect such a difference with an alpha error of 5% and a beta error of 20%, a minimum of 90 patients per arm were to be accrued in a two-year period. The response rate was analyzed by means of 95% confidence intervals (95% CI) and by chi-square test. Response rates were computed and compared according to the intention-to-treat approach, in that all randomized patients were included in the analyses.
Early progressions and deaths, toxic deaths, early withdrawals and deaths from other causes were included as failures. In order to assess the independent effect of the experimental treatment on the probability of response, after adjustment for imbalances between the two groups in factors predicting for response, a logistic regression model was used [19] , with probability of response as the dependent variable. The following covariates were included in the initial model: treatment (E vs. Q , PS ( > 0 vs. 0), adjuvant chemotherapy (no vs. yes) measured baseline tumor area ( > vs. <22 cm 2 ), age ( < vs. >65 years) sex (M vs. F). Covariates not significantly contributing to the likelihood of the model were removed from it by means of a backward procedure.
PFS and overall survival were calculated using the Kaplan-Meier method [20] and compared by means of the log-rank test.
Results
Patient characteristics
The characteristics of the patients enrolled in the two treatment arms are reported in Table 1 . There was a higher number of female patients and a lower number of patients receiving prior adjuvant chemotherapy in E as compared to C. This latter difference is explained by a higher number of patients with metastatic disease at diagnosis in E (13 patients) vs. C (6 patients). The proportion of tumor-related symptomatic patients was similar in the two arms, 30% vs. 35%, and this finding " Treatment was discontinued because no further tumor shrinkage was observed in more than two consecutive response evaluations two months apart from each other. completes the general picture of fairly good-prognosis patients accrued in this study. The median time from diagnosis of metastatic disease to randomization was 29 and 32 days for C and E patients, respectively. These figures have wide ranges (1-1011 days and 1-388 days, respectively) due to occasional patients with a very long natural history of their disease without treatment prior to study entry.
Compliance
The median time on treatment was shorter in the control arm than in E ( Table 2 ). The percentage of patients on treatment at two, four, six and eight months was 96%, 55%, 35% and 14% in C and 95%, 74%, 42%, and 22% in E. The most frequent reason for treatment discontinuation was progression, but 11% of patients discontinued chemotherapy in both arms because no further tumor shrinkage was observed in > 2 consecutive response evaluations 2 months apart from each other.
The total number of cycles administered (2 months each) was 210 in the control arm and 268 in the experimental arm. Of these 89% and 86%, respectively, were administered at full doses.
Toxicity
One toxic death occurred in the control arm and one in the experimental arm. The cause was neutropenic sepsis Response rate (%), (95% CI) 2(2) 11 (11) 46 (47) 36 (35) 9 (8) 27 (24) 44 (40) 22 (20) 13 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) 32(24-42) P = 0.0008 in patients with diarrhaea and dehydration in both cases. The baseline PS in these patients was 2 and 0, respectively, and the toxic deaths occurred on the first and second MTX -> 5-FU administration, respectively. Table 3 reports the incidence of toxicity in the two arms. Overall the two regimens were well tolerated. The toxicity of the bolus part was very similar in the two arms. As expected, significantly more cases of stomatitis and hand-foot syndrome were observed in the alternating treatment due to the infusional part. Diarrhaea was more common in the experimental arm as well.
Treatment outcome
Nine percent of patients in each arm were not evaluable for response. This was due to rapid clinical deterioration in seven patients, early toxic deaths in two patients, refusal to continue treatment after the first drug administration in four patients, death for non tumor related causes before evaluation in four patients. According to the intention-to-treat principle, all these patients were included in the analyses of response as failures, and in the PFS and survival analysis. Tumor lesions were measured by CTor MRI in 63% of cases (59% in C, 67% in E), ultrasound in 31% (34% in C and 29% in E), and chest X-rays in 6% (7% in C and 4% in E).
The results of the intention to treat analysis (n -214 patients) indicated an overall response rate of 13% (95% CI: 7%-21%) in the control arm and 32% (95% CI: 24%-42%) in the experimental arm, with a highly significant P-value (P = 0.001) ( Table 4) .
Nine CR were observed in E vs. two in C. All of them occurred in patients with liver involvement only. The median baseline tumor area in patients achieving CR was 10.5 cm 2 (range 3-73 cm 2 ). Six CR were achieved after one cycle of treatment, three after two cycles and two after three cycles. Evaluation of these CR was done by ultrasound in six patients and CT scan in five. No patient underwent surgery after CR, however, two patients in the control arm were operated after achieving a PR; these two patients were rendered disease-free by surgery and they were still disease-free at the time of this analysis. Among partial responders (38 patients), the median maximum tumor shrinkage was 66% in C and 69% and E. Among them 0 of 11 PR in C and 3 of 27 PR in E achieved greater than 90% max tumor shrinkage.
The median time to response was 59 and 65 days in Estimates are derived from a logistic regression model, using objective response as the dependent variable. All covariates were dichotomized. the control and experimental arm, respectively, and no patient achieved response after the third cycle.
Due to the imbalances occurred at randomization between the two treatment arms in the M: F ratio, in the proportion of patients who had received prior adjuvant therapy and in the distribution of dominant metastatic sites, a stratified analysis was carried out for each of these factors (Table 5) : a higher response rate in E was observed in all strata, with no evidence of interaction (= effect modification) between treatment and any of these factors.
Finally, in order to assess the independent effect of treatment on the probability of response, while simultaneously adjusting for variables potentially associated with response, a multivariate logistic regression model was fitted to the data, with objective response (yes/no) as the dependent variable. The following covariates were included in the model: assigned treatment (E vs. C), sex, age (< vs. >65 years), ECOG performance status (0 vs. > 0), previous adjuvant therapy, and total measured tumor area (< vs. > 22 cm 2 ). The results of this analysis (Table 6 ) indicate that the treatment was the most important independent variable associated with the probability of response. The relative odds of response 36 Figure 2 . K a p l a n -M e i e r progression-free survival curves for all patients. were 3.1 times higher in E as compared to C (P = 0.002). ECOG PS, total measured tumor area and prior adjuvant therapy were also independent variables significantly associated with response: the odds of response doubled in patients with PS = 0 (P = 0.05) and baseline measured tumor area < 22 cm 2 (P = 0.05). Prior adjuvant treatment resulted in three times lower chances of responding (P -0.02). No significant association between age or sex and the probability of response was observed.
The median response duration was 7 months in C vs. 9.5 months in E.
PFS was signficantly longer in E (median PFS = 4.3 months vs. 6.2, P -0.0029) with a 33% reduction in the rate of progression (odds ratio = 0.66, 95% CI: 0.49-0.86) (Figure 2 ). Overall survival was not signficantly different in the two arms (median OS = 14.1 months vs. 14.8 months, P -0.18)) with an odds ratio of 0.81, (95% CI: 0.64-1.1) (Figure 3 ). Estimated survival rates at two years were 13% for C and 25% in E.
Quality of life was thoroughly assessed on 54 patients (23 patients in C and 31 in E) through 445 completed forms. No difference was observed between the treatment arms as to paired comparisons regarding the psychological, activity and symptoms related scores on this limited population of patients treated at four institutions.
Treatment after failure of first-line chemotherapy
The majority of patients treated with sequential MTX -> 5-FU were given infusional 5-FU as second-line chemo- therapy. Since a) the value of second-line chemotherapy in prolonging survival has recently been established [5, 6] and b) we obtained highly significant differences between the arms in terms of response rates and PFS, but not overall survival, we retrospectively collected the data regarding second-and third-line treatment. Approximately 40% of patients received no further chemotherapy after failure of front-line treatment, while one fourth of the entire population went on to receive even third-line chemotherapy. Table 7 reports the chemotherapy regimens administered in these settings. Eighty percent of patients in the control arm received infusional 5-FU as second or third line (48 patients over 60). The great majority of these cases received protracted CI [21] , with few cases receiving the 24-hour schedule of infusional 5-FU [22] . Only a minority of patients received irinotecan because at the time this study began the camptothecin analogue was not available in Italy. Among the other agents employed, the most common were mitomycin C and the oral fluoropyrimidines. No CR were seen in these clearly progressive patients where it was not possible to formally assess the objective response rate. However, the median time from progression to death was substantially longer in C vs. E as a probable consequence of the higher antitumor activity of second-and third-line chemotherapy in patients in C compared to those in E.
Discussion
The major endpoint of this study was to demonstrate that alternating, schedule-specific biochemical modulation of 5-FU is more active than standard modulated bolus 5-FU. In general, standard modulated bolus 5-FU continues to be either the RPMI weekly 5-FU regimen with high-dose LV [23] or the Mayo Clinic regimen of monthly 5-FU + low-dose LV [24] . Nevertheless at the time the study was launched, 1995, a number of strong factors addressed our choice to consider MTX -» 5-FU among the standard regimens for this disease. In fact a) our latest randomized large scale study on bolus 5-FU + LV in this disease indicated 11% response rate and a MSTof only nine months [18] ; b) large studies done by others in 1995 [25] [26] [27] suggested that the efficacy of modulated bolus 5-FU + LV was lower than that reported in earlier studies and this suggestion was later confirmed [28, 29] ; c) at the time this study was designed, the metaanalysis comparing bolus 5-FU vs. sequential MTX -» 5-FU showed significantly higher response rates, longer PFS and overall survival compared to unmodulated bolus 5-FU [30] , while the metaanalysis on 5-FU vs. 5-FU + LV showed no difference in overall survival [31] . For all these reasons none of the collaborating centers wanted 5-FU + LV as standard comparator arm. Indeed, as a reflection of this general feeling, sequential MTX -> 5-FU has been tested in a large randomized clinical trial in the adjuvant setting of this disease that began accrual in Italy in 1995 [32] .
Originally we wanted to have irinotecan as predefined second-line chemotherapy on every suitable patient from either arm; that would have allowed to have overall survival as primary endpoint of the study. Because irinotecan was not made available to us at the time of trial design, we thought that it was unrealistic to expect survival differences from a study where patients in the control arm would likely have received infusional 5-FU upon progression and thus we chose response rate as primary endpoint.
Almost three times higher response rate was obtained in the experimental arm with a significantly longer PFS (6 vs. 4 months). With all the limitations connected with response evaluation, it is reassuring that the high response rates and long PFS that our group obtained in the previous phase II studies [12, 13] were confirmed in this phase III trial. A word of caution need to be spent about the CRs. Half of them were evaluated by ultrasound which might have overestimated the treatment benefit in a disease where in general the CR rate is extremely low.
The higher activity of the alternating regimen could be very easily explained by the addition of CI 5-FU to bolus 5-FU in the E arm compared to C, rather than to the whole schedule specific modulation strategy [33] . However, CI 5-FU is known to afford only approximately 10% response rate in patients resistant to bolus 5-FU [34] . This would support the hypothesis that an additional gain could be obtained by our strategy on top of simply alternating the two schedules.
A series of recent phase III studies using hybrid regimens of bolus/infusional 5-FU [28, 35] , chronomodulated 5-FU [8, 36] or combinations of 5-FU plus oxaliplatin [8, 37] or irinotecan [38] have shown response rates in the 30%-50% range and PFS values in the six to nine months range in randomized settings. The results of our experimental arm fall into these ranges at the cost of very low toxicity and expenses. Furthermore the survival data in our study are similar to those obtained with the latest regimens mentioned above (range 14-17 months).
We are still pursuing this schedule specific biochem-ical modulation preferring alternating bolus-infusional 5-FU. In fact, the back to back strategy, represented in part by the de Gramont regimen, has produced very low activity (22% response rate) in the latest reported phase III trial with this regimen [33] as compared to the results reported in earlier trials by the same group [28, 39] . Our plans of development are to conduct a series of phase II studies that incorporate the other active new agents in our alternating regimen in an effort to further potentiate the activity of the bolus or the infusional part, since toxicity appears to allow so. Based upon a British report [40] , mitomycin C has been added to the infusional part of our regimen in a phase II study that has just closed accrual. Since the bolus part needs more 'work'of refinement, oxaliplatin is added to MTX -> 5-FU in the ongoing phase II study and will consider irinotecan to be added as well. We think that our regimen of schedule-specific biochemical modulation represents one of the most active way of giving 5-FU presently available and since it is well tolerated, we are pursuing it as the basis for the development of combination regimens with the new active compounds that are now so promising in this disease.
